Sat. Oct 12th, 2024

The Houstonian Review

Reviewing Only The Best of Houston

Biotech firm Moleculin touts strong cash position, clinical trials in Q3 earnings call

1 min read

Moleculin officials discussed results in some of the company’s COVID-19 therapeutic drug trials, as well as cash that is anticipated to fund operations through 2024

Leave a Reply

Your email address will not be published.

Generated by Feedzy